Merck, 05092802-1VL, 22Rv1

Biochem/physiol Actions
22Rv1 is a human prostate carcinoma epithelial cell line derived from a xenograft that was serially propagated in mice after castration-induced regression and relapse of the parental, androgen-dependent CWR22 xenograft. The cell line expresses prostate specific antigen (PSA). Growth is weakly stimulated by dihydroxytestosterone and lysates are immunoreactive with androgen receptor antibody by Western blot analysis. Growth is stimulated by epidermal growth factor (EGF) but is not inhibited by transforming growth factor β-1 (TGF β-1). This cell line is tumorigenic in nude mice.
Human Xenograft Prostate
STR-PCR Data: Amelogenin: X,Y
CSF1PO: 10,11
D13S317: 9,12
D16S539: 12
D5S818: 11,12
D7S820: 10,11
THO1: 6,9.3
TPOX: 8
vWA: 15,21
Preparation Note
RPMI 1640 without phenol red (Sigma R7509) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS)
Split sub-confluent cultures (70-80%) 1:5 to 1:10 i.e. seeding at 2-4x10,000 cells/cm² using 0.25% trypsin or trypsin/EDTA; 5% CO₂; 37°C.
Other Notes
Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information.
This cell line is part of the European Collection of Authenticated Cell Cultures (ECACC), an international repository managed by the United Kingdom Health Security Agency (UKHSA). No licensing agreement is required when either this cell line or the DNA extracted from it are used for internal research purposes only. Any other use of these products is prohibited without the express written permission of UKHSA. Inquiries regarding authorized use of this cell line or its genomic DNA may be directed to [email protected].